Detalhe da pesquisa
1.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
N Engl J Med
; 389(24): 2221-2232, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952131
2.
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
Diabetes Obes Metab
; 25(7): 1932-1941, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36945734
3.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
N Engl J Med
; 377(9): 839-848, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28854085
4.
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
N Engl J Med
; 377(8): 723-732, 2017 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28605603
5.
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
Am Heart J
; 229: 61-69, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32916609
6.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 375(4): 311-22, 2016 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27295427
7.
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
Diabetes Obes Metab
; 21(6): 1437-1444, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30793465
8.
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
Diabetologia
; 61(1): 58-65, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28913543
9.
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
Diabetologia
; 61(1): 48-57, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28913575
10.
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Nat Med
; 2024 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38796653
11.
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
Obesity (Silver Spring)
; 31(1): 111-122, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36502289